Benign Prostatic Hyperplasia - Pipeline Review, H1 2017

Date: May 30, 2017
Pages: 113
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: B314BDE4A12EN
Leaflet:

Download PDF Leaflet

Benign Prostatic Hyperplasia - Pipeline Review, H1 2017
Benign Prostatic Hyperplasia - Pipeline Review, H1 2017

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Benign Prostatic Hyperplasia - Pipeline Review, H1 2017, provides an overview of the Benign Prostatic Hyperplasia (Male Health) pipeline landscape.

Benign Prostatic Hyperplasia (BPH) is a non-cancerous enlargement of the prostate, a small gland that encircles the urethra in males and produces a fluid that makes up part of semen. Symptoms include decreased strength of the urine stream, dribbling after urination, pain during urination, waking at night to urinate, difficulty starting a urine stream. Treatment options for BPH include surgery and medications.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Benign Prostatic Hyperplasia - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Benign Prostatic Hyperplasia (Male Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Benign Prostatic Hyperplasia (Male Health) pipeline guide also reviews of key players involved in therapeutic development for Benign Prostatic Hyperplasia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 9, 6, 3, 1, 9, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively.

Benign Prostatic Hyperplasia (Male Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Benign Prostatic Hyperplasia (Male Health).
  • The pipeline guide reviews pipeline therapeutics for Benign Prostatic Hyperplasia (Male Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Benign Prostatic Hyperplasia (Male Health) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Benign Prostatic Hyperplasia (Male Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Benign Prostatic Hyperplasia (Male Health)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Benign Prostatic Hyperplasia (Male Health).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Benign Prostatic Hyperplasia (Male Health) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Benign Prostatic Hyperplasia - Overview
Benign Prostatic Hyperplasia - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Benign Prostatic Hyperplasia - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Benign Prostatic Hyperplasia - Companies Involved in Therapeutics Development
Addex Therapeutics Ltd
AndroScience Corp
Aphios Corp
BCWorld Pharm Co Ltd
Biolab Farmaceutica Ltda
Chong Kun Dang Pharmaceutical Corp
Curadis GmbH
Dongkook Pharmaceutical Co Ltd
GL Pharm Tech Corp
Hanmi Pharmaceuticals Co Ltd
Health Ever Bio-Tech Co Ltd
Jeil Pharmaceutical Co Ltd
Kaken Pharmaceutical Co Ltd
MEI Pharma Inc
Meiji Seika Pharma Co Ltd
Mezzion Pharma Co Ltd
Monosol Rx LLC
Nymox Pharmaceutical Corp
Ono Pharmaceutical Co Ltd
OPKO Health Inc
SK Chemicals Co Ltd
SOM Biotech SL
Sophiris Bio Inc
Vantia Therapeutics
XuanZhu Pharma Co Ltd
Yungjin Pharm Co Ltd
Benign Prostatic Hyperplasia - Drug Profiles
(dutasteride + tadalafil) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(solifenacin succinate + tamsulosin hydrochloride) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(tadalafil + tamsulosin hydrochloride) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(tadalafil + tamsulosin hydrochloride) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ADX-68692 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ASC-JM.X2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AUS-131 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BCWPE-004 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BL-214 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CR-1447 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fadanafil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fedovapagon - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fexapotide triflutate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KKM-1202 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
L-1AD3 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MCS-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NCE-403 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ONO-8430506 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
S-0131632 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
S-40542 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Steroidal 5-Alpha Reductase for Benign Prostatic Hyperplasia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SOM-2391 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SOM-2393 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Sperol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Antagonize GPR54 for Womens Health, Male Health and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tadalafil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
talaporfin sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tamsulosin hydrochloride CR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tamsulosin hydrochloride DR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tamsulosin hydrochloride SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tertomotide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
topsalysin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TT-701 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
udenafil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
YBH-1603 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
YOB-1604 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Benign Prostatic Hyperplasia - Dormant Projects
Benign Prostatic Hyperplasia - Discontinued Products
Benign Prostatic Hyperplasia - Product Development Milestones
Featured News & Press Releases
May 08, 2017: NYMOX Files For Approval of First In Class Prostate Drug in Europe
May 03, 2017: NYMOX Files For Marketing Approval For Fexapotide Triflutate in Europe
Mar 29, 2017: Nymox Provides Update on Fexapotide Development
Dec 14, 2016: CFDA Granted Approval forPhase I/II/III Clinical Trials of Sihuan Pharmaceutical’s Internally Developed Innovative Patented New Drug - Fadanafil
Nov 29, 2016: Nymox Reports Additional Positive Results From Completed Fexapotide BPH Phase 3 Studies Showing Significant Early Response and First-Line Efficacy
Sep 20, 2016: Addex collaborators publish new data on negative allosteric modulator ADX68692
May 05, 2016: Sophiris Bio To Present Topsalysin Phase 3 Data from Positive PLUS-1 Study as a Late Breaking Poster During the 111th American Urological Association Annual Meeting
Apr 01, 2015: Nymox Announces Phase 3 BPH Studies
Dec 15, 2014: Sophiris Bio Reports Administrative Interim Analysis for the "PLUS-1" Phase 3 Trial of PRX302 for Benign Prostatic Hyperplasia
Nov 02, 2014: Nymox NX-1207 BPH Pivotal Phase 3 U.S. Studies NX02-0017 and NX02-0018 Fail to Meet Primary Efficacy Endpoints
Sep 02, 2014: Sophiris Bio Reports Completion of Enrollment in the "PLUS-1" Phase 3 Trial of PRX302 for Benign Prostatic Hyperplasia
Jul 22, 2014: Nymox Announces Positive Efficacy Results in Phase 3 Repeat Injection Trial of NX-1207 for BPH
Jul 15, 2014: Nymox Announces Completion of Enrollment for Second BPH Re-Injection Study
Jun 17, 2014: Nymox Reports Positive Update on Nerve Sparing and Sexual Function Preservation in Men Treated With NX-1207
Jun 11, 2014: Nymox Reports Positive New Safety Study Data for Phase 3 BPH Drug
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Benign Prostatic Hyperplasia, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd.1), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd.1), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Benign Prostatic Hyperplasia - Pipeline by Addex Therapeutics Ltd, H1 2017
Benign Prostatic Hyperplasia - Pipeline by AndroScience Corp, H1 2017
Benign Prostatic Hyperplasia - Pipeline by Aphios Corp, H1 2017
Benign Prostatic Hyperplasia - Pipeline by BCWorld Pharm Co Ltd, H1 2017
Benign Prostatic Hyperplasia - Pipeline by Biolab Farmaceutica Ltda, H1 2017
Benign Prostatic Hyperplasia - Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2017
Benign Prostatic Hyperplasia - Pipeline by Curadis GmbH, H1 2017
Benign Prostatic Hyperplasia - Pipeline by Dongkook Pharmaceutical Co Ltd, H1 2017
Benign Prostatic Hyperplasia - Pipeline by GL Pharm Tech Corp, H1 2017
Benign Prostatic Hyperplasia - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2017
Benign Prostatic Hyperplasia - Pipeline by Health Ever Bio-Tech Co Ltd, H1 2017
Benign Prostatic Hyperplasia - Pipeline by Jeil Pharmaceutical Co Ltd, H1 2017
Benign Prostatic Hyperplasia - Pipeline by Kaken Pharmaceutical Co Ltd, H1 2017
Benign Prostatic Hyperplasia - Pipeline by MEI Pharma Inc, H1 2017
Benign Prostatic Hyperplasia - Pipeline by Meiji Seika Pharma Co Ltd, H1 2017
Benign Prostatic Hyperplasia - Pipeline by Mezzion Pharma Co Ltd, H1 2017
Benign Prostatic Hyperplasia - Pipeline by Monosol Rx LLC, H1 2017
Benign Prostatic Hyperplasia - Pipeline by Nymox Pharmaceutical Corp, H1 2017
Benign Prostatic Hyperplasia - Pipeline by Ono Pharmaceutical Co Ltd, H1 2017
Benign Prostatic Hyperplasia - Pipeline by OPKO Health Inc, H1 2017
Benign Prostatic Hyperplasia - Pipeline by SK Chemicals Co Ltd, H1 2017
Benign Prostatic Hyperplasia - Pipeline by SOM Biotech SL, H1 2017
Benign Prostatic Hyperplasia - Pipeline by Sophiris Bio Inc, H1 2017
Benign Prostatic Hyperplasia - Pipeline by Vantia Therapeutics, H1 2017
Benign Prostatic Hyperplasia - Pipeline by XuanZhu Pharma Co Ltd, H1 2017
Benign Prostatic Hyperplasia - Pipeline by Yungjin Pharm Co Ltd, H1 2017
Benign Prostatic Hyperplasia - Dormant Projects, H1 2017
Benign Prostatic Hyperplasia - Dormant Projects, H1 2017 (Contd.1), H1 2017
Benign Prostatic Hyperplasia - Discontinued Products, H1 2017

LIST OF FIGURES

Number of Products under Development for Benign Prostatic Hyperplasia, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017

COMPANIES MENTIONED

Addex Therapeutics Ltd
AndroScience Corp
Aphios Corp
BCWorld Pharm Co Ltd
Biolab Farmaceutica Ltda
Chong Kun Dang Pharmaceutical Corp
Curadis GmbH
Dongkook Pharmaceutical Co Ltd
GL Pharm Tech Corp
Hanmi Pharmaceuticals Co Ltd
Health Ever Bio-Tech Co Ltd
Jeil Pharmaceutical Co Ltd
Kaken Pharmaceutical Co Ltd
MEI Pharma Inc
Meiji Seika Pharma Co Ltd
Mezzion Pharma Co Ltd
Monosol Rx LLC
Nymox Pharmaceutical Corp
Ono Pharmaceutical Co Ltd
OPKO Health Inc
SK Chemicals Co Ltd
SOM Biotech SL
Sophiris Bio Inc
Vantia Therapeutics
XuanZhu Pharma Co Ltd
Yungjin Pharm Co Ltd
Skip to top


Ask Your Question

Benign Prostatic Hyperplasia - Pipeline Review, H1 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: